Ventilan

Quick links to important sections

Ventilan

Selected form

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Ventilan

What is Ventilan? Overview

Property Description
Active Ingredient Salbutamol (or Albuterol)
Pharmacological Class Selective Beta-2 Adrenergic Agonists
Primary Forms Inhalation Suspension (MDI), Inhalation Solution, Tablets
Common Use Rescue medication for acute airway constriction
Origin Synthetic Compound

What Type of Medicine is Ventilan (Salbutamol)?

Ventilan is a trade name for the drug Salbutamol, which is known internationally by its INN (International Nonproprietary Name) and as Albuterol in the U.S. It is officially classified as a bronchodilator belonging to the pharmacological class of Selective Beta-2 Adrenergic Agonists. This compound is a synthetic substance that functions as a Short-Acting Beta-Agonist (SABA), a feature that is clinically recognized for providing rapid intervention in acute respiratory episodes. This class of medicine is recognized for its ability to open constricted airways by stimulating specific receptors.


Composition and General Purpose of This Bronchodilator

This product is a single active ingredient medicine containing Salbutamol sulfate. Unlike combination products, its action is singularly focused on the beta-2 receptors. The general therapeutic purpose is to achieve rapid bronchodilation by causing the swift relaxation of the bronchial smooth muscles surrounding the air passages in the lungs. This mechanism swiftly causes airway widening, cementing Ventilan's vital role as a rescue medication intended for the immediate relief of sudden breathing distress, such as when breathing becomes temporarily difficult due to a known respiratory trigger.


Inhaled and Oral Forms of Ventilan

Ventilan is manufactured in several core dosage forms, including the pressurized inhalation suspension (MDI) and the inhalation solution for nebulization. The primary route of administration for achieving a fast-acting effect is inhalation. For systemic use, the drug is also produced in tablets and syrup, which are administered via the oral route, often preferred for pediatric patients or those unable to utilize an inhaler effectively, though inhalation is generally chosen when immediate symptomatic relief is required.

Regulatory References

  1. Sabumalin (Salbutamol) in the Union Register of medicinal products - European Commission

What side effects are possible with Ventilan?

Possible Side Effects and Safety Information

The safety profile of Ventolin (albuterol/salbutamol) is established through official government regulatory documents, detailing possible adverse reactions and required safety precautions.

Adverse Reactions by Frequency

The following side effects are documented based on frequency of occurrence:

Frequency Common Side Effects (Examples)
Very Common (ge 1/10) Tremor (shakiness)
Common (ge 1/100 to <1/10) Headache, Tachycardia (fast heartbeat), Muscle cramps, Throat irritation
Uncommon Palpitations (pounding heart), Mouth and throat irritation
Rare Hypokalaemia (low potassium levels), Peripheral vasodilatation
Very Rare Paradoxical bronchospasm, Hypersensitivity reactions, Hyperactivity

Serious Adverse Reactions

Regulatory documents highlight rare but potentially severe risks that require immediate medical attention:

  • Paradoxical Bronchospasm: A severe and sudden worsening of breathing and wheezing immediately following inhalation. This is a life-threatening reaction that requires immediate discontinuation of the medication.
  • Immediate Hypersensitivity: Rare, severe allergic reactions, including anaphylaxis, angioedema (swelling), urticaria (hives), and collapse.
  • Cardiovascular Effects: Increases in heart rate and blood pressure, with documented potential for cardiac arrhythmias and myocardial ischaemia (heart oxygen deprivation).

Safety Considerations and Restrictions

  • Contraindications: The medicine is strictly contraindicated for individuals with a known hypersensitivity to any of its components. Non-intravenous formulations are also contraindicated for the management of uncomplicated premature labor or threatened abortion.
  • Dose Restriction: The recommended dose must not be exceeded due to the risk of serious cardiovascular effects and fatalities associated with excessive use.
  • Population Specific: Caution is required in patients with pre-existing cardiovascular disorders, diabetes mellitus, hyperthyroidism, or convulsive disorders. Safety has not been established for children under 4 years of age in certain indications.

Overdose and Emergency Response

Overdose and when to seek help

The information in this section is based on official government regulatory documents (e.g., FDA, EMA SmPC) and describes the documented manifestations and required emergency actions for Ventilan (Salbutamol) overdose.

Documented Overdose Presentations and Manifestations

Official labeling describes that overdose results primarily in an exaggeration of known pharmacological effects, often classified as sympathomimetic effects. Documented signs include Tachycardia (excessively rapid heart rate), Palpitations, Fine Tremor, Restlessness, and Headache.

Severe Outcomes and Required Emergency Actions

Overdose can lead to severe and potentially life-threatening complications involving the metabolic and cardiovascular systems. These serious outcomes include Hypokalemia (abnormally low serum potassium levels), Lactic Acidosis, and severe Cardiac Arrhythmias.

Mandatory Emergency Action: Due to the documented risks of life-threatening events, the regulatory guidance strictly requires that individuals seek immediate medical attention or contact emergency services immediately upon the recognition of any signs or symptoms of overdose.

Management and Monitoring

The documented management strategy is primarily symptomatic and supportive treatment. This often includes procedures such as continuous ECG monitoring and Potassium repletion to correct hypokalemia. Although no specific antidote is known, the regulatory text notes that a cardioselective beta-blocking agent may be used under extreme caution in a supervised medical setting.

Therapeutic Uses of Ventilan

Ventilan (Salbutamol) is a common rescue medication used for managing symptomatic relief in clinical situations involving symptoms related to acute or episodic changes. This therapeutic approach focuses on addressing conditions and symptoms that create noticeable physiological strain and interference with functional stability.


Managing Conditions Characterized by Acute Episodes

Ventilan is commonly used across conditions presenting with acute episodes, primarily including Asthma and Chronic Obstructive Pulmonary Disease (COPD), and is relevant in conditions involving episodic or fluctuating manifestations such as chronic bronchitis and emphysema. It is applied across domains where additional symptomatic support is needed due to symptoms associated with acute or disruptive episodes. This provides support that helps ease the overall symptom burden during symptomatic periods, and may be part of symptomatic management in conditions where functional stability becomes affected.


Easing Distressing Symptoms of Airflow Limitation

This medication helps address symptom clusters that may become intense or disruptive, specifically shortness of breath (dyspnea), wheezing, and chest tightness. It is relevant for managing symptoms that interfere with daily comfort. The supportive relief contributes to easing the overall symptom load, and contributes to improved comfort during periods of heightened symptoms.


Situational Use and Management of Triggered Episodes

Ventilan is commonly used when short-term symptomatic assistance is needed, such as during episodes of sudden symptom escalation due to external triggers like allergens or irritants. Furthermore, it is also applied proactively for symptomatic relief, as it is relevant before anticipated physical exertion to may assist in managing exercise-induced bronchospasm. This supports patients during difficult episodes by easing distress and contributes to a sense of stability when symptoms become more noticeable in specific scenarios.

Quick Fact: Helps manage Wheezing and Shortness of Breath

Regulatory References

  1. NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

Official Eligibility and Non-Eligibility for Ventilan

Regulatory labeling for Ventilan (salbutamol/albuterol) defines its appropriate use by establishing clear exclusions and restrictions for certain patient populations.

Contraindications (Must Not Use)

  • Hypersensitivity: Individuals with a history of allergy or hypersensitivity to salbutamol/albuterol or any other component of the specific formulation are contraindicated.
  • Obstetric Use: Non-intravenous formulations (e.g., inhalers, oral tablets) are contraindicated for use in managing uncomplicated premature labor or threatened abortion.

Age-Related Eligibility

  • Pediatric Patients: The safety and effectiveness of the inhaled formulation (e.g., HFA inhaler) are generally not established in children younger than four years of age.
  • Older Adults: Use in the elderly may require caution, and treatment is often initiated at the minimum effective dose due to potential increased sensitivity.

Populations Requiring Special Caution

Official documents mandate caution and often require close monitoring for patients with coexisting medical conditions, including cardiovascular disorders (e.g., coronary insufficiency, arrhythmias), hypertension, diabetes mellitus, or thyrotoxicosis.

Pregnancy and Lactation

Use during pregnancy is typically permitted only if the expected benefit to the mother is greater than any potential risk to the fetus. For breastfeeding women, use is generally not recommended unless the benefit outweighs the potential risk to the neonate, as salbutamol is thought to be secreted in breast milk.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Ventilan (salbutamol) may interact with certain medicines, primarily through additive effects on the body's systems or by counteracting its main therapeutic action. The official regulatory profile emphasizes pharmacodynamic interactions and specific exposure modification notes.

Contraindicated Combinations

Non-selective beta-Adrenoreceptor Blocking Agents, such as Propranolol, should generally not be co-administered. This combination can result in pharmacodynamic antagonism, blocking the bronchodilating effect of salbutamol and potentially leading to severe bronchospasm.

Clinically Significant Interactions

The most significant documented interactions require caution or monitoring due to shared effects:

  • Diuretics, Corticosteroids, and Xanthine Derivatives (e.g., Theophylline): Co-administration may potentiate the risk of hypokalemia (low serum potassium). Monitoring of serum potassium levels is advised, especially in patients with acute severe asthma.
  • Monoamine Oxidase Inhibitors (MAOIs) and Tricyclic Antidepressants (TCAs): Extreme caution is necessary as these agents may amplify salbutamol's effects on the vascular system.
  • Digoxin: Salbutamol has been documented to potentially decrease serum levels of Digoxin, which may necessitate level monitoring to maintain therapeutic effect.

Other Considerations

Patients with pre-existing severe heart disease should be monitored closely when using salbutamol with other sympathomimetic agents due to potential additive cardiovascular effects.

Mechanism of Action

How Ventilan Works at the Biological Level

Ventilan (active ingredient salbutamol/albuterol) modulates the sympathetic nervous system signaling pathway within the pulmonary tissues. Its mechanism is characterized by two phases: selective receptor interaction and the resultant intracellular cascade, which leads to the relaxation of bronchial smooth muscle.

beta2-Receptor Targeting and Activation

This pharmacodynamic mechanism begins at the cell surface, where the active substance acts as a selective short-acting agonist on mathbfbeta2-adrenergic receptors. These receptors are located primarily on airway smooth muscle cells. This binding initiates a G-protein-coupled signal transduction cascade that directly modulates the physiological process of muscle contraction.

Intracellular Relaxation Cascade

Following receptor activation, the cascade stimulates adenylyl cyclase, which increases the level of the intracellular second messenger cyclic AMP (cAMP). This cAMP modifies molecular steps by activating Protein Kinase A (PKA). PKA mediates the reduction of intracellular calcium ions ( Ca^2+) and inhibits myosin phosphorylation, both of which are required for muscle contraction. The physiological consequence of this intracellular mechanism is the direct decrease in bronchial smooth muscle tension.

Dosage and Administration Information

How to Use Ventilan (Salbutamol/Albuterol)

Ventilan (salbutamol or albuterol) must be used strictly according to specific administration guidelines to ensure correct dosing and drug delivery. These instructions govern the use of the medicine across its various available forms.


Official Administration and Dosing

Dosage Form Route of Administration Standard Single Dose (Adults) Frequency Constraint
Pressurized Inhaler (pMDI) Oral Inhalation 2 inhalations (puffs) May be repeated every 4 to 6 hours
Nebuliser Solution Oral Inhalation 2.5 mg to 5 mg Intermittent dosing requires a minimum time interval between treatments
Oral Tablets Oral 2 mg or 4 mg Usually taken three or four times daily

Preparation and Procedural Steps

The pressurized metered-dose inhaler requires specific preparation and maintenance. The inhaler must be shaken well immediately before each use. If the device is new, has been dropped, or has not been used for more than two weeks, it must be primed by releasing several test sprays into the air. The plastic actuator should be cleaned regularly (e.g., weekly) to prevent the buildup of residue that could block the spray nozzle.

For nebuliser solution, dilution with sterile normal saline to a total volume of 2 mL is often required prior to use. The nebuliser solution must never be swallowed or injected. Patients must not exceed the maximum daily dose, and the prescribed interval between doses must be strictly observed.

If a dose is missed, the standard procedure is to take the missed dose as soon as it is remembered, unless it is near the time for the next scheduled dose, in which case the missed dose should be skipped.

Recent Clinical Evidence

Ventilan: Recent Clinical Evidence

Clinical Research for the Relief of Acute Airflow Limitation

The research base for Ventilan's active ingredient, Salbutamol, includes Randomized Controlled Trials (RCTs). These studies examine symptom patterns in patients with conditions like asthma and COPD during periods of increased symptom activity. Researchers monitored objective measurements of air flow, such as Forced Expiratory Volume in 1 second ( FEV1), following a single administration and compared them to observations from a control group. Studies reported measurements of time-dependent change in pulmonary function and patterns observed in patient-reported symptom scores during acute episodes.

How Studies Measured Immediate Airflow Improvement

The core evidence base examined objective measures in the lungs, using spirometry to capture the amount of air a person could forcibly exhale ( FEV1). This measure was studied alongside monitoring physiological strain and outcomes related to functional imbalance to provide insight into short-term changes.

Evidence for Situational Use in Preventing Exercise-Induced Breathing Difficulty

Research has explored studying the agent in specific scenarios through single-dose, randomized controlled challenge studies. The key outcome measured was the change in air flow following an exercise challenge. Studies reported that the effects were short-lived, and the difference in observed patterns decreased when the agent was used on a daily, regular basis compared to its episodic use.

Research Data on Long-Term Outcomes and Usage Patterns

Insight into the long-term effects on pulmonary function and disease progression over many years of exposure is currently not supported by controlled, long-term trials. The evidence for these long-term exposure patterns is limited, relying on observational studies that tracked usage patterns. Some observational research described patterns where frequent, regular use was associated with subsequent recordings of acute episodes.

Evidence in Specific Patient Groups

Research established findings for Adults and Adolescents (12 years and older), and Children aged 4 years and older. However, subgroup findings are uncertain for patients with multiple co-existing conditions, as they are often excluded from core RCTs.

What the Research Found in Young Children

A significant limitation noted in the official regulatory record is the evidence gap for the youngest patients. The regulatory record notes that findings regarding safety and effectiveness are not definitive for children younger than 4 years, and the research provides limited information on dosing for this group.

Areas of Research Uncertainty and Study Gaps

Key limitations persist: long-term effects are not fully established by controlled trials. Furthermore, while the data show patterns related to the association between frequent use and adverse events, because the evidence is observational, a direct causal link is not fully established.

Frequently Asked Questions (FAQ)

Common questions about Ventilan (FAQ)

Q: How quickly does Ventilan usually start working after using it?

According to official product information, the bronchodilating effect of the inhaled forms of Ventilan typically starts very quickly, often within a few minutes of administration. This rapid onset of action is characteristic of its use as a rescue medication for acute breathing symptoms.


Q: What does it mean if Ventilan doesn't seem to last very long for me?

Official regulatory labels indicate that the therapeutic effect of the drug generally lasts for 4 to 6 hours. If the effect does not last the expected time, official warnings note that this may be a sign that the patient’s condition is deteriorating, which should be brought to a healthcare provider’s attention.


Q: Can Ventilan be used by people who also have heart conditions?

Official information indicates that Ventilan should be used with caution in patients with pre-existing cardiovascular disorders. These conditions include coronary insufficiency (reduced blood flow to the heart muscle), arrhythmias (irregular heartbeats), or high blood pressure. Regulatory labeling indicates that close medical oversight may be required for use in these populations.


Q: Is Ventilan known to interact with commonly used blood pressure medicines?

Yes, official documents warn against co-administering Ventilan with non-selective beta-blocking agents, which are a class of blood pressure medicine. This combination can result in pharmacodynamic antagonism, meaning the beta-blocker may counteract the bronchodilating effect of Ventilan.


Q: What is the difference between Ventilan and other types of inhalers I see advertised?

Ventilan is officially classified as a Short-Acting Beta-Agonist (SABA). This means its primary function is to provide rapid relief for sudden, acute symptoms. This mechanism is different from other classes of inhalers, such as long-acting agents or inhaled corticosteroids, which are typically used for routine, long-term control of airway inflammation.


Q: Are there different forms of Ventilan available, like an inhaler versus a nebulizer solution?

Yes, regulatory documents confirm that the medicine is manufactured in various forms. These commonly include the pressurized metered-dose inhaler (pMDI), an inhalation solution designed for use with a nebulizer machine, and oral forms such as tablets or syrup.


Q: Is it true that Ventilan can sometimes cause low potassium levels?

Official documents list Hypokalaemia, which is the clinical term for low serum potassium levels, as a documented adverse reaction that can occur. While possible, official safety profiles generally describe this as a rare event. Official warnings note that clinical oversight may involve monitoring serum potassium levels, especially in patients with acute severe breathing difficulty.


Q: Why is it important to check if Ventilan interacts with certain heart rhythm drugs?

The importance of checking for interactions stems from the potential for Ventilan to amplify cardiovascular effects when used with certain medications, such as Digoxin. Official information states that Ventilan may affect the levels of Digoxin, which could necessitate monitoring to ensure therapeutic effectiveness.


Q: What is the recommended period of time between uses of Ventilan?

Regulatory administration instructions for the inhaled forms of Ventilan specify that repeated use should generally not occur more frequently than every 4 to 6 hours. Observing the minimum time interval between treatments is described in official labeling as a requirement for administration.


Q: Is there any information on using Ventilan during pregnancy?

Regulatory documents state that use during pregnancy is typically considered only when the expected benefit to the mother is greater than any potential risk to the fetus. Regulatory documents describe that the decision for use in pregnancy involves weighing the expected benefit to the mother against the potential risk to the fetus.


Q: Do studies suggest any long-term effects from regularly using Ventilan?

The official record indicates that insight into long-term effects on pulmonary function is not fully established by controlled trials over many years. Observational research has described patterns where frequent, regular use was associated with subsequent recordings of acute episodes. A direct causal link for these patterns is not fully established.


Q: Does alcohol consumption affect how Ventilan works or increase side effects?

Official patient guidance often indicates that there are generally no known direct interactions between this medication and moderate consumption of alcohol. Patients are generally advised in official guidance to discuss the use of all substances, including alcohol, with a healthcare provider.


Q: Is Ventilan the brand name for a generic medicine?

Ventilan is a trade name for the active ingredient Salbutamol, which is known internationally by its INN (International Nonproprietary Name) and as Albuterol in the U.S. It is a single active ingredient medicine available under various generic and brand names globally.


Q: Can Ventilan be used if I have diabetes or thyroid problems?

Official documents mandate that the medication should be used with caution in patients with pre-existing conditions such as diabetes mellitus or hyperthyroidism (an overactive thyroid). This is due to the potential for the drug to affect these underlying conditions.


Q: Is it possible to develop a tolerance to Ventilan over time?

Official warnings note that an increased need for the medication, such as using it more often than prescribed, may be a sign that the underlying respiratory condition is deteriorating. This is not necessarily tolerance, but a worsening condition that requires clinical evaluation.


Q: Does taking Ventilan affect my ability to drive or operate machinery?

Some documented side effects, such as dizziness or shakiness, may affect the ability to drive or operate complex machinery. Official documents note that caution is advised, and patients are encouraged to be aware of how the medicine affects them before engaging in activities that require full mental alertness.


Q: Are there certain foods or supplements that should be avoided while using Ventilan?

Official patient information often states that there are no known interactions between the medicine and specific foods or drinks. However, official patient guidance recommends discussing the use of any supplements or herbal products with a healthcare provider.


Q: Is Ventilan used only for sudden breathing trouble or for preventing it too?

Regulatory documents confirm that Ventilan is officially indicated for the immediate treatment of acute bronchospasm, which is sudden breathing trouble. It is also indicated for the prevention of bronchospasm that is specifically triggered by exercise.


Q: What are the common reasons why someone might be told they cannot use Ventilan?

The primary reason the drug is strictly contraindicated is a known hypersensitivity or allergy to the active ingredient, Salbutamol, or to any other component of the specific formulation. Additionally, certain non-intravenous forms are contraindicated for use in managing premature labor.


Q: Do official patient information leaflets describe any interactions with herbal remedies?

Official patient guidance indicates that there is often not enough regulatory information to confirm the safety of complementary medicines or herbal remedies when used with this drug. Official patient guidance suggests discussing the use of any such products with a healthcare provider.


Q: Is Ventilan a controlled substance or scheduled medication?

Ventilan (salbutamol/albuterol) is generally not classified as a controlled substance in the United States by the Drug Enforcement Administration (DEA). Its status is defined by regional drug regulatory bodies.


Q: What is the difference between the dry powder inhaler and the metered dose inhaler form of Ventilan?

Regulatory documents describe the pressurized metered-dose inhaler (pMDI) as delivering a spray or aerosol. In contrast, dry powder forms require different preparation steps and administration techniques. Both are designed to deliver the medicine via inhalation, but the method of delivery is distinct.


Q: Can Ventilan be used for a cough that is not related to asthma?

The drug is officially indicated for conditions that involve bronchospasm, or airway narrowing, which commonly occurs in asthma. It is not officially indicated for the treatment of a general cough alone.


Q: What does the research say about Ventilan's use in infants?

Official regulatory records specifically note that the safety and effectiveness findings are not definitive for children younger than four years of age. Research provides limited, non-definitive information on dosing and outcomes for the youngest patient populations, including infants.


Q: Are there specific storage instructions mentioned for Ventilan to maintain its effectiveness?

Yes, official instructions require the product to be stored at a controlled room temperature, typically between 20 C and 25 C. Pressurized canisters must be kept away from heat or open flames, and some solutions require protection from light to maintain their stability and effectiveness.


Q: Can Ventilan make my voice sound different or cause hoarseness?

Although not listed as a common side effect, hoarseness or a rough, scratchy sound to the voice has been described in post-marketing or uncommon adverse reaction reports. Users should note that these effects are generally rare.

How should Ventilan be stored and disposed of?

The storage and disposal of Ventilan (salbutamol/albuterol) must strictly adhere to regulatory labeling to ensure product stability and safety.

Official Storage Conditions

Ventilan products, such as the inhalation aerosol, must be stored at controlled room temperature, typically between 20 C and 25 C (68 F and 77 F). Pressurized canisters must not be exposed to temperatures exceeding 49 C (120 F) and should be kept away from heat or open flame.

Stability and Protection

The inhalation solution requires protection from light and should be stored in its original packaging. All medicine must be kept out of the sight and reach of children.

Disposal Requirements

The pressurized canister must never be punctured or thrown into a fire or incinerator. The inhaler must be discarded when the dose counter reaches zero or by the expiration date. Disposal of all unused or expired product must be done in accordance with local regulations.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Ventilan found in:

A-Z Index: